Was doing some digging around. Thought this was a good article on 2nd line NSCLC after failure of immunotherapy in 1st line.
Current options for these 2nd line patients:
(1) doublet chemo if patient received PD-1 monotherapy in 1st line
(2) single agent chemo if patient received PD-1 + chemo combo in 1st line
(3) get the patient into a clinical trial
High unmet need. Described as the "holy grail" in the article.
https://www.medpagetoday.com/clinical-challenges/asco-thoracic-cancer/87279
Ann: Efti with Keytruda shows encouraging activity in lung cancer, page-20
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $1.270M | 3.611M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 286261 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 253490 | 7 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |